Pharmacokinetics and pharmacodynamics of diclofenac in the presence and absence of glibenclamide in the rat

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 3, 2008, Pages 68-76

  León Reyes, María R ^a   Castañeda Hernández, Gilberto ^b   Ortiz, Mario I ^c  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE HIDALGO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DICLOFENAC; GLIBENCLAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ARTICLE; BIOAVAILABILITY; DOSE RESPONSE; DRUG INTERACTION; FEMALE; ORAL DRUG ADMINISTRATION; PAIN; PAIN ASSESSMENT; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; GLYBURIDE; HYPOGLYCEMIC AGENTS; PAIN; PAIN MEASUREMENT; RATS; RATS, WISTAR;

EID: 58149133944     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3ks39     Document Type: Article

References (33)

1. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 1988; 35:244-285.
2. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol, 1996; 102:9-21.
3. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA, 1999; 96:7563-7568.
4. + channels by diclofenac. Eur J Pharmacol, 2002; 438:85-91.
5. Ortiz MI, Granados-Soto V, Castañeda-Hernández G. The NOcGMP-K(+) channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav, 2003; 76:187-195.
6. Alves DP, Tatsuo MA, Leite R, Duarte ID. Diclofenac-induced peripheral antinociception is associated with ATP-sensitive K+ channels activation. Life Sci, 2004; 74:2577-2591.
7. North RA. Twelfth Gaddum memorial lecture. Drug receptors and the inhibition of nerve cells. Br J Pharmacol, 1989; 98:13-28.
8. Tonussi CR, Ferreira SH. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol, 1994; 251:173-179.
9. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet, 1997; 33:184-213.
10. Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol, 1983; 25:389-394.
11. Zecca L, Ferrario P, Costi P. Determination of diclofenac and its metabolites in plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr, 1991; 567:425-432.
12. Torres-López JE, López-Muñoz FJ, Castañeda-Hernández G, Flores-Murrieta FJ, Granados-Soto V. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. J Pharmacol Exp Ther, 1997; 282:685-690.
13. Flores-Murrieta FJ, Ko HC, Flores-Acevedo DM, López-Muñoz FJ, Jusko WJ, Sale ME, Castañeda-Hernández G. Pharmacokineticpharmacodynamic modeling of tolmetin antinociceptive effect in the rat using an indirect response model: a population approach. J Pharmacokinet Biopharm, 1998; 26:547-557.
14. Al-Balla SR, El-Sayed YM, Al-Meshal MA, Gorda MW. The effects of cholestyramine and colestipol on the absorption of diclofenac in man. Int J Clin Pharmacol Ther, 1994; 32:441-445.
15. + channels. Annu Rev Pharmacol Toxicol, 1993; 33:597-637.
16. Picazo A, Castañeda-Hernández G, Ortiz MI. Examination of the interaction between peripheral diclofenac and gabapentin on the 5% formalin test in rats. Life Sci, 2006; 79:2283-2287.
17. García-López P, Salas R. Bioavailability of diclofenac after intramuscular administration to rats with experimental spinal cord injury. J Pharmacol Toxicol Methods, 1999; 42:99-101.
18. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 1983; 16:109-110.
19. Malmberg AB, Yaksh TL. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther, 1992; 2631:136-146.
20. Granados-Soto V, López-Muñoz FJ, Hong E, Flores-Murrieta FJ. Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat. J Pharmacol Exp Ther, 1995; 272:352-356.
21. Reyes-Gordillo K, Muriel P, Castañeda-Hernández G, Favari L. Pharmacokinetics of diclofenac in rats intoxicated with CCL4, and in the regenerating liver. Biopharm Drug Dispos, 2007; 28:415-422.
22. Le Bars D, Gozariu M, Cadden SW. Acute pain measurement in animals. Part I. Ann Fr Anesth Reanim, 2001; 20:347-365.
23. Ortiz MI, Castañeda-Hernández G. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats. Eur J Pain, 2008; 12:233-241.
24. Welch SP, Dunlow LD. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists, a common mechanism of action?. J Pharmacol Exp Ther, 1993; 267:390-399.
25. Granados-Soto V, Terán-Rosales F, Rocha-González HI, Reyes-García G, Medina-Santillán R, Rodríguez-Silverio J, Flores-Murrieta FJ. Riboflavin reduces hyperalgesia and inflammation but not tactile allodynia in the rat. Eur J Pharmacol, 2004; 92:35-40.
26. Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, Marroum P. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther, 1999; 66:9-15.
27. Zharikova O, Fokina V, Nanovskaya T, Ravindran S, Hill R, Mattison D, Hankins GDV, Ahmed M. Identification of the major human hepatic and placental enzymes responsible for the metabolism of glyburide. Am J Obstet Gynecol, 2007; 197:S111.
28. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4-hydroxylation in human liver. Life Sci, 1993; 52:29-34.
29. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol, 1999; 58:787-796.
30. Shen S, Marchick MR, Davis MR, Doss GA, Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol, 1999; 12:214-222.
31. Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action?. Acta Diabetol, 1997; 34:239-244.
32. Arreola-Espino R, Urquiza-Marín H, Ambriz-Tututi M, Araiza-Saldaña CI, Caram-Salas NL, Rocha-González HI, Mixcoatl-Zecuatl T, Granados-Soto V. Melatonin reduces formalininduced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol, 2007; 577:203-210.
33. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton), 2007; 12:261-266.